Macupatide / Obesity / Overweight · Phase 1 Trial

A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes

ClinicalTrials.gov · August 14, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a Phase 1 trial registration for macupatide (LY3532226), a novel agent in development for obesity and overweight, with planned enrollment of 60 participants. The study aims to characterize safety, tolerability, and pharmacokinetics over approximately 4 months, but no results are yet posted in this registry record.

What was studied

Phase 1, Interventional, Randomized, Parallel, Double masking, Basic Science purpose. Obesity, Overweight; age from 18 Years; to 65 Years; accepts healthy volunteers. Intervention: Macupatide ＋ placebo; Eloralintide + placebo; Macupatide Dose A + Eloralintide; Macupatide Dose B + Eloralintide. Compared with: Placebo — Placebo Comparator. n = 60. 3 sites: Japan.

Key findings

Safety

No efficacy endpoints are measured; this is a Phase 1 safety and tolerability study.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

Phase 1 safety and tolerability study in a planned enrollment of 60 participants; no results posted; designed to characterize adverse events and pharmacokinetics rather than efficacy.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration (assessed at End of Study (Week 25))

DesignPhase 1, Interventional, Randomized, Parallel, Double masking, Basic Science purpose

PopulationObesity, Overweight; age from 18 Years; to 65 Years; accepts healthy volunteers

Sample size60

InterventionMacupatide ＋ placebo; Eloralintide + placebo; Macupatide Dose A + Eloralintide; Macupatide Dose B + Eloralintide

ComparatorPlacebo — Placebo Comparator

Setting3 sites: Japan

Reported figures

Quoted from the source exactly as published.

Planned enrollment60

Study phasePhase 1

Primary endpointNumber of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, End of Study (Week 25)

Study duration per participantapproximately 4 months

Inpatient unit stays2 stays of 3–5 nights each

Caveats

No results are reported in this registry record; the trial is not yet recruiting.
No efficacy endpoints are measured; this is a Phase 1 safety and tolerability study.
Study setting and geographic location not specified in registry record.
Randomization, blinding, and allocation concealment procedures not detailed in registry record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Phase 1, placebo-controlled, multiarm design; appropriate for initial safety assessment.

Directness

limited

Primary endpoint is safety; efficacy not measured. Surrogate pharmacokinetic data planned.

Consistency

insufficient

No results reported; consistency cannot be assessed from a registry record.

Risk of bias

insufficient

Registry record does not describe randomization, blinding, or allocation concealment methods.

Sample adequacy

limited

Estimated enrollment 60 participants; typical for early Phase 1 dose exploration, not powered for efficacy.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07765511). This is a study registration, not published results. Lead sponsor: Eli Lilly and Company. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 60 participants (ESTIMATED). Conditions: Obesity, Overweight. Interventions: DRUG: Macupatide; DRUG: Eloralintide; DRUG: Placebo. Primary outcome measures: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration , End of Study (Week 25). Brief summary: The main purpose of this study is to assess how well macupatide, when dosed alone and in combination with eloralintide, is tolerated and what side effects may occur in participants with obesity or overweight without Type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 4 months and will include 2 stays in the Clinical Research Unit (CRU), each lasting 3-5 nights.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

MacupatideEli Lilly and CompanyObesityNCT07765511OverweightEloralintide